[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100568524":3},{"organization":4,"armGroups":7,"interventions":24,"overallOfficials":46,"centralContacts":50,"locations":60,"responsibleParty":74,"collaborators":55,"id":77,"slug":55,"hasResults":78,"nctId":79,"briefTitle":80,"officialTitle":80,"acronym":55,"eligibilityCriteria":81,"healthyVolunteers":78,"sex":82,"minAge":83,"maxAge":84,"enrollmentInfo":85,"targetDuration":55,"studyType":88,"phases":89,"briefSummary":91,"conditions":92,"keywords":55,"overallStatus":94,"whyStopped":55,"lastUpdateSubmitDate":95,"lastUpdatePostDateStruct":96,"startDateStruct":99,"completionDateStruct":101,"leadSponsor":103,"locationsCount":104},{"fullName":5,"class":6},"Stanford University","OTHER",[8,16,20],{"label":9,"type":10,"description":11,"interventionNames":12},"Mediterranean Diet\u002FGLP1a\u002FMetformin","EXPERIMENTAL","1. 16 weeks of following a Mediterranean diet: a mostly plant-based diet that includes vegetables, whole grains, whole fruits, legumes, nuts and seeds, with fish being the primary animal protein, and olive oil the primary fat.\n2. 3 months washout\n3. 16 weeks using GLP1 agonist: Dosing will be titrated per clinical guidelines and as per FDA approved clinical protocols.\n4. 3 months washout\n5. 16 weeks of using metformin: Dosing will initiate at 500mg TID and increased to 1000mg BID after one week.",[13,14,15],"Drug: Metformin","Drug: GLP-1A","Dietary Supplement: MED",{"label":17,"type":10,"description":18,"interventionNames":19},"Metformin\u002FMediterranean Diet\u002FGLP1a","1. 16 weeks of using metformin: Dosing will initiate at 500mg TID and increased to 1000mg BID after one week.\n2. 3 months washout\n3. 16 weeks of following a Mediterranean diet: a mostly plant-based diet that includes vegetables, whole grains, whole fruits, legumes, nuts and seeds, with fish being the primary animal protein, and olive oil the primary fat.\n4. 3 months washout\n5. 16 weeks using GLP1 agonist: Dosing will be titrated per clinical guidelines and as per FDA approved clinical protocols.",[13,14,15],{"label":21,"type":10,"description":22,"interventionNames":23},"GLP1a\u002FMetformin\u002FMediterranean Diet","1. 16 weeks using GLP1 agonist: Dosing will be titrated per clinical guidelines and as per FDA approved clinical protocols.\n2. 3 months washout\n3. 16 weeks of using metformin: Dosing will initiate at 500mg TID and increased to 1000mg BID after one week.\n4. 3 months washout\n5. 16 weeks of following a Mediterranean diet: a mostly plant-based diet that includes vegetables, whole grains, whole fruits, legumes, nuts and seeds, with fish being the primary animal protein, and olive oil the primary fat.",[13,14,15],[25,32,38],{"type":26,"name":27,"description":28,"armGroupLabels":29,"otherNames":30},"DRUG","Metformin","16 weeks of using metformin: Dosing will initiate at 500mg TID and increased to 1000mg BID after one week.",[21,9,17],[31],"MET",{"type":26,"name":33,"description":34,"armGroupLabels":35,"otherNames":36},"GLP-1A","16 weeks using GLP1a: Dosing will be titrated per clinical guidelines and as per FDA approved clinical protocols.",[21,9,17],[37],"Glucagon-like peptide-1 analog",{"type":39,"name":40,"description":41,"armGroupLabels":42,"otherNames":43},"DIETARY_SUPPLEMENT","MED","16 weeks of following a Mediterranean diet: a mostly plant-based diet that includes vegetables, whole grains, whole fruits, legumes, nuts and seeds, with fish being the primary animal protein, and olive oil the primary fat.",[21,9,17],[44,45],"Mediterranean Diet","energy-restricted Mediterranean diet",[47],{"name":48,"affiliation":5,"role":49},"Tracey McLaughlin, MD","PRINCIPAL_INVESTIGATOR",[51,57],{"name":52,"role":53,"phone":54,"phoneExt":55,"email":56},"Alina Choi, BS","CONTACT","7144884516",null,"linachoi@stanford.edu",{"name":58,"role":53,"phone":55,"phoneExt":55,"email":59},"Jasmine Yang, BA","jasminey@stanford.edu",[61],{"facility":5,"status":55,"city":62,"state":63,"zip":64,"country":65,"cosmosGeoPoint":66,"geoPoint":71,"contacts":72},"Stanford","California","94305","United States",{"type":67,"coordinates":68},"Point",[69,70],-122.16608,37.42411,{"lat":70,"lon":69},[73],{"name":52,"role":53,"phone":55,"phoneExt":55,"email":56},{"type":49,"investigatorFullName":75,"investigatorTitle":76,"investigatorAffiliation":5,"oldNameTitle":55,"oldOrganization":55},"Tracey McLaughlin","Professor of Medicine (Endocrinology)","100568524",false,"NCT06682351","Heterogeneity of Diabetes: Integrated Muli-Omics to Identify Physiologic Subphenotypes and Evaluate Targeted Prevention","Inclusion Criteria:\n\n* BMI ≥23 (≥22 in Asians) kg\u002Fm2 but \\\u003C 45 kg\u002Fm2\n* HbA1c 5.7-8.0% while not on antihyperglycemic medications\n\nExclusion Criteria:\n\n* Recent (\\\u003C6mos) CVD event\n* active malignancy, kidney\u002Fliver disease pregnancy\u002Flactation, chronic inflammatory disease, eating disorder, bariatric surgery\n* history of acute pancreatitis\n* family or personal history of medullary thyroid cancer\n* current use of antihyperglycemic, diabetogenic, or weight loss medications (washout allowed if approved by primary physician)\n* heavy alcohol use\n* hct \\\u003C30, creatinine \\> 1.4, ALT\\> 3x ULN\n* physical activity \\>2 hours\u002Fday\n* inability to come to Stanford CTRU for metabolic testing","ALL","18 Years","75 Years",{"count":86,"type":87},200,"ESTIMATED","INTERVENTIONAL",[90],"PHASE4","The study team will invite participants with prediabetes or mild diabetes (HbA1c 5.7-7.0) to join a 5-year research study that will define subphenotypes of type 2 diabetes based on underlying physiology (eg insulin resistance, beta-cell dysfunction, incretin defect, liver insulin resistance) and then test the hypothesis that response to three first-line treatments will vary according to metabolic subphenotype. Variables of interest include glucose, cardiovascular risk markers, and weight. Treatments include Mediterranean diet, metformin, and a GLP-1 agonist. Participants will go through an initial screening, followed by three treatment periods, each lasting 4 months with 3 month washout in-between treatment periods. This study will help us understand how personalized treatments can help control blood glucose, reduce cardiovascular risk, and manage weight. While there may be minor side effects-like slight discomfort from blood tests, gastrointestinal symptoms from some of the medications, and small radiation exposure from DXA body scans-the treatments offered in this study have all been well studied and are known to lower risk for diabetes and cardiovascular disease",[93],"Prediabetes \u002F Type 2 Diabetes","NOT_YET_RECRUITING","2024-11-07",{"date":97,"type":98},"2024-11-12","ACTUAL",{"date":100,"type":87},"2024-11",{"date":102,"type":87},"2027-12",{"name":5,"class":6},1]